Showing results (311-320 of 339) with videos related to

Sort By:
Pageof 34
JAMA Network Open|July 7, 2026
Patient-Centered Approach to Surgical Prevention of Ovarian Cancer: A Nonrandomized Clinical TrialKaren H Lu, Barbara M Norquist, Gary B Chisholm, et al.
Cancer Discovery|May 13, 2022
Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian CancerChang-Suk Chae, Tito A Sandoval, Sung-Min Hwang, et al.
Nature Communications|September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancerPanagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
Plos One|November 14, 2019
Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemiaGayle P Pouliot, James Degar, Laura Hinze, et al.
JCI Insight|December 22, 2020
Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AMLZuzana Tothova, Anne-Laure Valton, Rebecca A Gorelov, et al.
Cell Stem Cell|September 30, 2020
MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi AnemiaAlfredo Rodríguez, Kaiyang Zhang, Anniina Färkkilä, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2018
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder CancerQiang Li, Alexis W Damish, Zoë Frazier, et al.
JCO Precision Oncology|April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker AnalysesPanagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
Cancer Discovery|September 15, 2018
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer OrganoidsSarah J Hill, Brennan Decker, Emma A Roberts, et al.
British Journal of Cancer|December 10, 2021
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumoursPanagiotis A Konstantinopoulos, Su-Chun Cheng, Jeffrey G Supko, et al.
Pageof 34